Active Ingredient History

  • Now
Daprodustat is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Daprodustat was approved in Japan in June 2020 for the treatment of patients with anemia due to chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.   Wikipedia

  • Mol. Mass: 393.44
  • ALogP: 1.26
  • ChEMBL Molecule:
More Chemistry
daprodustat | gsk1278863


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue